Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
9.1
273.58%
Every year
—
6x
Every year
—
5 Years
Score9.1
Net Growth273.58%
Net TrendEvery year
Net Income Consistency—
Rev Growth6x
Rev TrendEvery year
Revenue Consistency—
Aurinia Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 50M to $ 283M and net income went from -$ 102M to $ 287M. Revenue increased in every one of those 5 years; net income in every one.
Between 2005 and 2025, revenue grew from $ 1M to $ 283M and net income went from -$ 29M to $ 287M. Revenue increased in 11 of those 20 years; net income in 11.
Aurinia Pharmaceuticals Inc currently holds a 20-year HDB Score of 4.7 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 15.45 | — |
1 Year2025-08-12 | $ 11.32 | 36.48% |
5 Years2021-08-12 | $ 15.26 | 1.25% |
10 Years2016-08-12 | $ 4.09 | 277.75% |
20 Years2006-08-11 | $ 1.17 | 13x |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 |
|---|---|---|---|---|---|
| Price | $ 15.45 | $ 11.32 | $ 15.26 | $ 4.09 | $ 1.17 |
| Return | — | 36.48% | 1.25% | 277.75% | 13x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 311M | $ 314M | $ 443M |
| 2025 | $ 283M | $ 287M | $ 397M |
| 2024 | $ 235M | $ 5M | $ 358M |
| 2023 | $ 175M | -$ 78M | $ 350M |
| 2022 | $ 134M | -$ 108M | $ 389M |
| 2021 | $ 45M | -$ 180M | $ 466M |
| 2020 | $ 50M | -$ 102M | $ 398M |
| 2019 | $ 318K | -$ 88M | $ 306M |
| 2018 | $ 463K | -$ 64M | $ 125M |
| 2017 | $ 420K | -$ 70M | $ 173M |
| 2016 | $ 173K | -$ 23M | $ 39M |
| 2015 | $ 235K | -$ 18M | $ 15M |
| 2014 | $ 278K | -$ 16M | $ 32M |
| 2013 | $ 948.56K | -$ 2M | $ 1M |
| 2012 | $ 6M | -$ 9M | $ 184.96K |
| 2011 | $ 927.52K | -$ 2M | $ 5M |
| 2010 | $ 3M | -$ 3M | $ 6M |
| 2009 | $ 4M | -$ 7M | $ 4M |
| 2008 | $ 3M | -$ 15M | $ 21M |
| 2007 | $ 2M | -$ 33M | $ 32M |
| 2006 | $ 3M | -$ 22M | $ 22M |
| 2005 | $ 1M | -$ 29M | $ 45M |
| 2004 | $ 1M | -$ 22M | $ 50M |
| 2003 | $ 7M | -$ 14M | $ 62M |
| 2002 | $ 11M | -$ 365.87K | $ 40M |
| 2001 | $ 5M | -$ 7M | $ 33M |
| 2000 | $ 902.77K | -$ 6M | $ 11M |
| IPO1999 | $ 1M | -$ 1M | $ 2M |
Explore beyond AUPH
You're looking at Aurinia Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
